Safety and Pharmacokinetic Effects of Oseltamivir Alone or in Combination With Amantadine

An Open-Label, Multiple Dose, Randomized, Three-Period Crossover Study in Healthy Volunteers to Evaluate the Effect of co-Administration of Amantadine 100 mg BID and Oseltamivir 75 mg BID on the Pharmacokinetic Properties of Amantadine and Oseltamivir.

This study is designed to assess the safety and pharmacokinetic effects of oseltamivir administration alone or in combination with amantadine in healthy volunteers.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Drug: oseltamivir phosphate; Drug: amantadine hydrochloride

• Study Type: Interventional
• Enrollment: 18
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • New Jersey
    • East Hanover, New Jersey, United States, 07936-1080
      • Novartis Investigative Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 45 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Healthy male or female subjects aged 18 to 45 years, and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests

• Vital signs within the following ranges:

  • oral body temperature 35.0 - 37.5°C
  • systolic blood pressure 90 - 140 mm Hg
  • diastolic blood pressure 50 - 90 mm Hg
  • pulse rate 40 - 90 bpm
• Female subjects of child bearing potential must be using double-barrier local contraception (for example, intra-uterine device plus condom, or spermicidal gel plus condom) or have been surgically sterilized at least 6 months prior before study start, with supportive clinical documentation OR Postmenopausal women must have no regular menstrual bleeding for at least 1 year prior to inclusion.
• Body mass index must be within 18 - 30 kg/m2. Subjects must weigh at least 50 kg.

Exclusion Criteria:

• Smokers (use of tobacco products in the previous 3 months). Smokers will be defined as those who report tobacco use or have a urine cotinine greater than 500 ng/mL
• Female subjects who are pregnant or lactating
• Participation in any clinical investigation involving medical intervention within 4 week prior to study start.
• Donation or loss of ≥ 400 mL of blood within 8 weeks prior to study start, or longer if required by local regulation.
• Significant illness within 2 weeks before study start.
• A past personal or close family medical history of clinically significant ECG abnormalities or of a prolonged QT-interval syndrome.
• History of autonomic dysfunction (for example, history of fainting).
• History of acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or untreated),
• History of clinically significant drug allergy or history of atopic allergy (asthma, urticaria, eczematous dermatitis). A known hypersensitivity to the study drug or to similar drugs.
• Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs, or which may jeopardize the subject in case of participation in the study, including bowel, gastrointestinal, renal, pancreatic, hepatic, hematological, immunological, or neurological disorders.

Other protocol-defined inclusion/exclusion criteria may apply

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
To characterize the pharmacokinetics of amantadine following twice daily administration alone or in combination with twice daily oseltamivir in healthy volunteers.
To characterize the pharmacokinetics of oseltamivir following twice daily administration alone or in combination with twice daily amantadine in healthy volunteers.

Secondary Outcome Measures

Outcome Measure
To assess the safety and tolerability of twice daily oseltamivir and twice daily amantadine when given alone and when given in combination.

Collaborators and Investigators

• Sponsor: Novartis
• Collaborators: Hoffmann-La Roche

Publications and helpful links

General Publications

• Morrison D, Roy S, Rayner C, Amer A, Howard D, Smith JR, Evans TG. A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination. PLoS One. 2007 Dec 12;2(12):e1305. doi: 10.1371/journal.pone.0001305.

Study record dates

Study Major Dates

• Study Start: August 1, 2006
• Study Completion (Actual): December 1, 2006

Study Registration Dates

• First Submitted: December 27, 2006
• First Submitted That Met QC Criteria: December 27, 2006
• First Posted (Estimate): December 28, 2006

Study Record Updates

• Last Update Posted (Estimate): November 30, 2007
• Last Update Submitted That Met QC Criteria: November 29, 2007
• Last Verified: November 1, 2007

More Information

Terms related to this study

• Keywords: Oseltamivir, amantidine, Symmetrel, Tamiflu
• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Peripheral Nervous System Agents; Antiviral Agents; Enzyme Inhibitors; Analgesics; Sensory System Agents; Analgesics, Non-Narcotic; Dopamine Agents; Antiparkinson Agents; Anti-Dyskinesia Agents; Oseltamivir; Amantadine
• Other Study ID Numbers: CSYO380A2101